CN112689512B - 用于治疗银屑病的组合物和方法 - Google Patents

用于治疗银屑病的组合物和方法

Info

Publication number
CN112689512B
CN112689512B CN201980050534.6A CN201980050534A CN112689512B CN 112689512 B CN112689512 B CN 112689512B CN 201980050534 A CN201980050534 A CN 201980050534A CN 112689512 B CN112689512 B CN 112689512B
Authority
CN
China
Prior art keywords
antibody
seq
psoriasis
week
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980050534.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112689512A (zh
Inventor
B·C·梁
S·勒伊斯
C·J·法里纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abby Center Co ltd
Original Assignee
Abby Center Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abby Center Co ltd filed Critical Abby Center Co ltd
Publication of CN112689512A publication Critical patent/CN112689512A/zh
Application granted granted Critical
Publication of CN112689512B publication Critical patent/CN112689512B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CN201980050534.6A 2018-05-29 2019-05-29 用于治疗银屑病的组合物和方法 Active CN112689512B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862677590P 2018-05-29 2018-05-29
US62/677590 2018-05-29
PCT/US2019/034423 WO2019232070A1 (en) 2018-05-29 2019-05-29 Compositions and methods for treatment of psoriasis

Publications (2)

Publication Number Publication Date
CN112689512A CN112689512A (zh) 2021-04-20
CN112689512B true CN112689512B (zh) 2025-09-05

Family

ID=68697289

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050534.6A Active CN112689512B (zh) 2018-05-29 2019-05-29 用于治疗银屑病的组合物和方法

Country Status (9)

Country Link
US (2) US12016921B2 (https=)
EP (1) EP3801590A4 (https=)
JP (1) JP7357646B2 (https=)
KR (1) KR102940600B1 (https=)
CN (1) CN112689512B (https=)
AU (1) AU2019279883B2 (https=)
CA (1) CA3101767A1 (https=)
IL (1) IL278978B2 (https=)
WO (1) WO2019232070A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US11690912B2 (en) * 2018-05-29 2023-07-04 Abcentra, Llc Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
EP4058042A4 (en) * 2019-11-12 2023-12-27 Abcentra, LLC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2025151468A1 (en) * 2024-01-08 2025-07-17 Abcentra, Llc Methods of identifying a subject for treatment with antibodies against oxidized low density lipoprotein using pericoronary fat attenuation index

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101951885A (zh) * 2007-12-28 2011-01-19 生物发明国际公司 制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
WO2008104194A1 (en) 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
US8557767B2 (en) * 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2274333A4 (en) * 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
KR20120111724A (ko) 2009-08-28 2012-10-10 제넨테크, 인크. 항-산화된 ｌｄｌ 항체를 이용한 치료 방법
MX2013003920A (es) * 2010-10-06 2013-06-03 Abbvie Inc Metodos para el tratamiento de la psoriasis.
WO2016024254A1 (en) 2014-08-15 2016-02-18 Fundació Hospital Universitari Vall D’Hebron-Institut De Recerca Therapy selection for psoriasis and psoriatic arthritis
US11690912B2 (en) 2018-05-29 2023-07-04 Abcentra, Llc Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101951885A (zh) * 2007-12-28 2011-01-19 生物发明国际公司 制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Serum lipid metabolism in psoriasis and psoriatic arthritis- an update;Aldona Pietrzak等;Arch Med Sci.;20180308;第15卷(第2期);摘要、第373页右栏第2段、表III *

Also Published As

Publication number Publication date
EP3801590A1 (en) 2021-04-14
EP3801590A4 (en) 2022-03-16
WO2019232070A1 (en) 2019-12-05
US20250161440A1 (en) 2025-05-22
IL278978B2 (en) 2026-01-01
CN112689512A (zh) 2021-04-20
JP7357646B2 (ja) 2023-10-06
IL278978A (en) 2021-01-31
KR20210044742A (ko) 2021-04-23
US12016921B2 (en) 2024-06-25
US20210205448A1 (en) 2021-07-08
AU2019279883A1 (en) 2021-01-21
KR102940600B1 (ko) 2026-03-18
CA3101767A1 (en) 2019-12-05
AU2019279883B2 (en) 2025-05-22
JP2021530438A (ja) 2021-11-11
IL278978B1 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
CN112689512B (zh) 用于治疗银屑病的组合物和方法
US11214621B2 (en) Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
AU2025205430A1 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
TW202037604A (zh) 治療掌蹠膿疱症之抗il-36r抗體
JP2021050204A (ja) 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
JP7671822B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
Zachariae et al. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis
CN119095617A (zh) 用于治疗患有头皮斑块型银屑病的受试者的方法
US20260098087A1 (en) Dosages of emactuzumab
JP2025176134A (ja) 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
HK40052952A (en) Compositions and methods for treatment of psoriasis
EP3952993B1 (en) Method of treating fumaric acid ester-resistant plaque psoriasis
CN121909045A (zh) 一种重组抗IL-23p19抗体治疗中重度银屑病的方法
KR20260057215A (ko) 결절성 양진 환자에서 피부 병변 및 소양증의 치료
TW202500184A (zh) 治療潰瘍性結腸炎之方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052952

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant